ORBITA-2 - Percutaneous coronary intervention for stable angina: A randomized, placebo-controlled trial

Reported from AHA 2023

Luis Ortega Paz interviews Rasha Al-Lamee and Christopher Rajkumar on the results of ORBITA-2 randomized placebo-controlled trial, which were presented at the AHA 2023 Congress in Philadelphia.

In stable angina patients with minimal antianginal medication and objective evidence of ischemia, PCI improved angina symptoms more than a placebo procedure, indicating better angina-related health.

Latest news from AHA 2023

Authors

Luis Ortega-Paz

Interventional cardiologist / Cardiologist

University of Florida College of Medicine – Jacksonville - Jacksonville, United States of America

Christopher Rajkumar

Interventional cardiologist / Cardiologist

Imperial College Healthcare NHS Trust - London, United Kingdom

Rasha Al-Lamee

Interventional cardiologist / Cardiologist

Imperial College School of Medicine - London, United Kingdom

Join the discussion

1 comment

  • Patricia Aubanel-Riedel 20 Nov 2023

    Iam so excited to see Orbita 2 results . Fist of all congrats! to a great work done from the leader Dr Al-Lamee to the whole team. I am so happy for the pts. We interventional cardiologist all knew by experience this was true, however, we needed the proof . Patients finally Will receive What is best for them, what they need and deserve. Patricia Aubanel-Riedel,M.D. México